Sanofi and C4X Discovery ink â¬414 M worldwide licensing deal
Sanofi and C4X Discovery ink â¬414 M worldwide licensing deal
16 April 2021 | News
Funding to be used for pre-clinical, potential development, regulatory, and commercialization of oral therapy for inflammatory diseases
Photo Credit: shutterstock
Sanofi and drug discovery company C4X Discovery (C4XD) have entered an exclusive worldwide licensing agreement worth up to €414 million for C4XD’s oral pre-clinical IL-17A inhibitor programme.
The deal will see Manchester University spinout C4XD receive an upfront payment of €7m, and up to a further €407m in potential development, regulatory, and commercialization milestones, of which €11m is in pre-clinical milestones.